Holmium Laser Versus Conventional TURBT for Non-Muscle-Invasive Bladder Cancer: Randomized Controlled Trial, 100 Patients
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov registered a prospective randomized controlled trial (NCT07534631) comparing holmium laser en-bloc resection (HoLERBT) with conventional transurethral resection (cTURBT) for treatment of non-muscle-invasive bladder cancer. A total of 100 patients will be randomized 1:1. The primary outcome is quality of pathological specimen assessed by presence of detrusor muscle. Secondary outcomes include perioperative complications, operative time, obturator nerve reflex, bladder perforation, positive surgical margins, persistent disease at second-look TURBT, and recurrence rates at 3 and 12 months.
What changed
NIH registered a new prospective randomized controlled trial on ClinicalTrials.gov comparing two surgical techniques for non-muscle-invasive bladder cancer. The study will enroll 100 patients randomized to holmium laser en-bloc resection or conventional transurethral resection. Primary endpoint is pathological specimen quality; secondary endpoints include complications, operative time, and recurrence rates at 3 and 12 months.
Clinical investigators and healthcare institutions conducting bladder cancer research should be aware of this trial for potential participation or competitive intelligence. Patients with suspected non-muscle-invasive bladder cancer may seek enrollment. The study adds to evidence on minimally invasive surgical approaches for bladder tumor resection.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder Cancer
N/A NCT07534631 Kind: NA Apr 16, 2026
Abstract
This study is a prospective randomized controlled trial comparing holmium laser en-bloc resection of bladder tumor (HoLERBT) with conventional transurethral resection of bladder tumor (cTURBT) in patients with suspected non-muscle-invasive bladder cancer (NMIBC).
A total of 100 patients will be randomly assigned in a 1:1 ratio to undergo either HoLERBT or cTURBT. The primary outcome is the quality of the pathological specimen, assessed by the presence of detrusor muscle. Secondary outcomes include perioperative complications, operative time, obturator nerve reflex, bladder perforation, positive surgical margins, persistent disease at second-look TURBT, and recurrence rates at 3 and 12 months, as well as recurrence-free survival.
This study aims to evaluate whether HoLERBT provides superior resection quality and improved clinical outcomes compared to conventional TURBT.
Conditions: Bladder Tumor (TURBT)
Interventions: Holmium Laser En-Bloc Resection of Bladder Tumor, Conventional Transurethral Resection of Bladder Tumor
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.